🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. Placebo to Basimglurant (Microcrystalline Cellulose Spheres (Vivapur 1000) and hard Gelatin Capsule, Opaque white body/Opaque white cap, Size 1), Basimglurant, Basimglurant

    Lacuna Pharma Pty Ltd

    Trigeminal neuralgia, Trigeminal neuralgia

    phase 3 small molecule active

    1 trial

  2. Placebo to Clostridium Botulinum neurotoxin type A (150 kD), CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS

    Merz Therapeutics GmbH

    Chronic migraine

    phase 3 small molecule active

    1 trial

  3. Placebo to Descartes-08, Descartes-08

    Cartesian Therapeutics

    generalized myasthenia gravis

    phase 3 small molecule active

    1 trial

  4. Placebo to Group B Streptococcus 6-Valent Polysaccharide Conjugate Vaccine (GBS6), Group B Streptococcus 6-Valent Polysaccharide Conjugate Vaccine (GBS6)

    Pfizer Australia Pty Ltd

    Group B streptococcus (GBS) disease

    phase 3 small molecule active

    1 trial

  5. Placebo to Guselkumab Solution for injection in pre-filled syringe 100 mg/ml., Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Psoriatic arthritis (PsA)

    phase 3 small molecule active

    1 trial

  6. Placebo to Ibuzatrelvir film-coated tablet, PF-07817883 Tablet

    Pfizer Australia Pty Ltd

    Covid-19 at high risk of progression to severe illness.

    phase 3 small molecule active

    1 trial

  7. Placebo to Imetelstat, -, -, IMETELSTAT

    Geron Netherlands B.V.

    Myelodysplastic syndromes (MDS)

    phase 3 small molecule active

    1 trial

  8. Placebo to Keytruda - Normal Saline Solution, GEMCITABINE, CISPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Cis-eligible Muscle-invasive bladder cancer.

    phase 3 small molecule active

    1 trial

  9. Placebo to MK-7240 (Tulisokibart), tulisokibart

    Merck Sharp and Dohme

    Crohn’s Disease or Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  10. Placebo to MK-7240, tulisokibart, tulisokibart

    Merck Sharp and Dohme

    Crohn’s Disease

    phase 3 small molecule active

    1 trial

  11. Placebo to Match Tinlarebant (LBS-008). Placebo tablets will be prepared similarly with microcrystalline cellulose used in place of the active drug substance. The placebo tablet is identical in size, appearance, and other physical properties to the LBS-008 tablet., LBS-008

    ELITE PHARMACEUTICALS INC /NV/

    Geographic Atrophy

    phase 3 small molecule active

    1 trial

  12. Placebo to Mexiletine granules for prolonged-release oral suspension 167 mg, 333 mg, and 500 mg, Mexiletine granules for prolonged-release oral suspension 333 mg, Mexiletine granules for prolonged-release oral suspension 500 mg, Mexiletine granules for prolonged-release oral suspension 167 mg

    Lupin Europe GmbH

    Myotonic Dystrophy type 1 and type 2 (DM1/DM2)

    phase 3 small molecule active

    1 trial

  13. Placebo to OXYMETAZOLINE HYDROCHLORIDE (Vehicle), STN1013800

    Santen Oy

    Acquired Blepharoptosis

    phase 3 small molecule active

    1 trial

  14. Placebo to Pembrolizumab, CISPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Locally Advanced Cervical Cancer

    phase 3 small molecule active

    1 trial

  15. Placebo to Ponsegromab (PF-06946860), CALCIUM LEVOFOLINATE PENTAHYDRATE, Ponsegromab (PF-06946860)

    Pfizer Australia Pty Ltd

    Cancer cachexia

    phase 3 small molecule active

    1 trial

  16. Placebo to Povorcitinib, Povorcitinib

    Incyte

    Vitiligo

    phase 3 small molecule active

    1 trial

  17. Placebo to Povorcitinib, Povorcitinib, Povorcitinib

    Incyte

    Prurigo Nodularis

    phase 3 small molecule active

    1 trial

  18. Placebo to Remdesivir - Saline, Remdesivir, PF-07817883 Tablet, Placebo to Ibuzatrelvir

    Pfizer Australia Pty Ltd

    Coronavirus Disease 2019 (COVID-19)

    phase 3 small molecule active

    1 trial

  19. Placebo to Remibrutinib (LOU064) 0 mg matching 00 mg film-coated tablet, TRIAMCINOLONE , Placebo to Remibrutinib (LOU064) 0 mg matching 00 mg film-coated tablet, LOU064, CLINDAMYCIN , LOU064, -

    Novartis Pharmaceuticals

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule active

    1 trial

  20. Placebo to Remibrutinib (LOU064) 00 mg film-coated tablet, LOU064

    Novartis Pharmaceuticals

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  21. Placebo to Remibrutinib (LOU064) XX mg film-coated tablet, LOU064, LOU064, Placebo to Remibrutinib (LOU064) XX mg film-coated tablet

    Novartis Pharmaceuticals

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule active

    1 trial

  22. Placebo to Remibrutinib (LOU064) film-coated tablets, LOU064

    Novartis Pharmaceuticals

    Secondary progressive multiple sclerosis

    phase 3 small molecule active

    1 trial

  23. Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device, TQJ230

    Novartis Pharmaceuticals

    Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  24. Placebo to Test and Comparator, DoriDuo, Mebocaína Anti-Inflam, 1.2 mg + 3 mg, comprimidos para chupar

    Medice Arzneimittel Pütter GmbH & Co. KG

    acute pharyngitis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources